OCUPHIRE PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.53 USD | +0.66% |
|
-3.16% | -49.17% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the call today to discus...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Companyâs lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1α and NF-B. The Inhibiting REF-1 reduces levels of vascular endothelial growth factor (VEGF) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. APX3330 is an oral tablet to be administered twice per day for the treatment of DR. The Companyâs pipeline candidates include APX2009 and APX2014. The Company is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as monotherapy or adjunctive therapy for other retinal indications such as DME, wAMD, and GA.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.52
USD
Average target price
19.33
USD
Spread / Average Target
+1,171.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.17% | 39.4M | |
| +55.32% | 819B | |
| -6.75% | 351B | |
| +13.56% | 329B | |
| +10.68% | 298B | |
| +16.57% | 242B | |
| +2.04% | 225B | |
| +13.31% | 217B | |
| +8.48% | 168B | |
| -2.81% | 158B |
- Stock Market
- Equities
- OCUP Stock
- News Ocuphire Pharma, Inc.
- Transcript : Ocuphire Pharma, Inc. - Special Call
